Physician profile
Joseph E Cesanek
NPI 1053327106
$6,968.79
in general payments reported to CMS, 2019-2025
38 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $454 · 2021: $50.00 · 2022: $676 · 2023: $1,308 · 2024: $1,404 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,258 · Education: $7.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,257.55 |
| Education | $7.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,021.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $942.44 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $818.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.78 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $477.55 | 2019-2023 | |
| Astellas Pharma US INC | $388.72 | 2019-2024 | Veozah |
| Pfizer INC. | $377.60 | 2019-2025 | |
| Abbvie INC. | $346.34 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Genzyme Corporation | $240.00 | 2020 | |
| Amgen INC. | $212.93 | 2019-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $176.44 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $171.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $139.73 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $136.76 | 2019-2021 | |
| Esperion Therapeutics, INC. | $103.79 | 2023-2025 | Nexletol |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cesanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.